GLP-1 agonists linked to adverse gastrointestinal events in weight loss patients
BMJ 2023; 383 doi: https://doi.org/10.1136/bmj.p2330 (Published 09 October 2023) Cite this as: BMJ 2023;383:p2330- Elisabeth Mahase
- The BMJ
The use of glucagon like peptide-1 (GLP-1) receptor agonists for weight loss has been linked to an increased risk of pancreatitis, gastroparesis, and bowel obstruction.1
A research team from the University of British Columbia, Canada, compared non-diabetic patients using GLP-1 agonists—4144 using liraglutide (Saxenda) and 613 using semaglutide (Ozempic/Wegovy)—with 654 people taking the weight loss agent bupropion-naltrexone.
The results, published in a short research letter in JAMA, showed that the use of GLP-1 agonists was associated with increased risk of pancreatitis (adjusted hazard ratio, 9.09 [95% confidence interval, 1.25 to 66.00]), bowel obstruction (HR, 4.22 [95% CI, 1.02 to 17.40]), and gastroparesis (HR, 3.67 [95% CI, 1.15 to 11.90]) but not biliary disease (HR, 1.50 [95% CI, 0.89 to 2.53]), when …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.